

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-64. (Cancelled).

65. (Currently Amended) A method for the treatment of at least one of myocardial infarction, [[and]] angina pectoris, acute cardiac insufficiency, energetic cardiac insufficiency, energetic-dynamic cardiac insufficiency, hypodynamic cardiac insufficiency, excitomotor cardiac insufficiency, hypoxemic cardiac insufficiency, primary cardiac insufficiency, compensated cardiac insufficiency, decompensated cardiac insufficiency, relative or stress cardiac insufficiency, and left ventricular cardiac insufficiency, comprising administering to a patient in need thereof at least one fumaric acid derivative selected from dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamide fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic oligomers of these compounds, and oxacarbocyclic oligomers of these compounds an effective amount of a pharmaceutical preparation comprising dimethyl fumarate, methyl hydrogen fumarate, or a combination thereof.

66-76 (Cancelled).

77. (Currently Amended) The method according to claim 65, wherein the

[[drug]] pharmaceutical preparation is administered in a form suitable for oral, rectal, transdermal, dermal, ophthalmological, nasal, pulmonary or parenteral application.

78. (Currently Amended) The method according to claim 77, wherein the [[drug]] pharmaceutical preparation is provided in the form of tablets, coated tablets, capsules, granulate, solutions for drinking, liposomes, nano particles, nano-capsules, micro-capsules, micro-tablets, pellets or powders and in the form of granules filled in capsules or sachets, micro-tablets filled in capsules or sachets, pellets filled in capsules or sachets, nano-particles filled in capsules or sachets or powder filled in capsules or sachets.

79. (Currently Amended) The method according to claim 78, wherein the [[drug]] pharmaceutical preparation is present in the form of nano particles, pellets or micro-tablets which may optionally be filled in sachets or capsules.

80. (Previously Presented) The method according to claim 78, wherein the solid oral dosage forms are provided with an enteric coating.

81. (Previously Presented) The method according to claim 79, wherein the solid oral dosage forms are provided with an enteric coating.

82. (Currently Amended) The method according to claim 65, wherein the amount of ~~the at least one fumaric acid derivative~~ dimethyl fumarate, methyl

hydrogen fumarate, or a combination thereof administered corresponds to 1 to 500 mg of fumaric acid.

83. (Previously Presented) The method of claim 65 in which only myocardial infarction is treated.

84. (Withdrawn) The method of claim 65 in which only angina pectoris is treated.

85. (New) The method of claim 65 wherein only at least one of acute cardiac insufficiency, energetic cardiac insufficiency, energetic-dynamic cardiac insufficiency, hypodynamic cardiac insufficiency, excitomotor cardiac insufficiency, hypoxemic cardiac insufficiency, primary cardiac insufficiency, compensated cardiac insufficiency, decompensated cardiac insufficiency, relative or stress cardiac insufficiency, and left ventricular cardiac insufficiency is treated.

86. (New) The method of claim 65 in which the only active ingredient for the treatment of at least one of myocardial infarction, angina pectoris, acute cardiac insufficiency, energetic cardiac insufficiency, energetic-dynamic cardiac insufficiency, hypodynamic cardiac insufficiency, excitomotor cardiac insufficiency, hypoxemic cardiac insufficiency, primary cardiac insufficiency, compensated cardiac insufficiency, decompensated cardiac insufficiency, relative or stress cardiac insufficiency, and left ventricular cardiac insufficiency, present in the pharmaceutical preparation is dimethyl fumarate, methyl hydrogen fumarate, or a combination thereof.

87. (New) The method of claim 86 in which the only active ingredient present in the pharmaceutical preparation is dimethyl fumarate.
88. (New) The method of claim 86 in which the only active ingredient present in the pharmaceutical preparation is methyl hydrogen fumarate.